Despite what the name suggests, Polycystic Ovary Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PCOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PCOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PCOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PCOS so challenging—and why understanding your unique experience matters.
So, how can the PCOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PCOS—and make progress.
Here’s what you’ll find at PCOSA:
✅ Reliable, science-backed information about what PCOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PCOS patients
🙋♀️ Advocacy to make sure PCOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PCOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
CONCLUSION: C. bungeana Turcz. and C. decumbens (Thunb.) Pers. possess a range of bioactive compounds with potential therapeutic effects on PCOS. The network pharmacology approach unveiled the multi-faceted interactions of these compounds with PCOS-related biological pathways, providing a foundation for the development of novel, multi-targeted therapeutic strategies for PCOS. Further experimental and clinical validation is required to translate these findings into tangible clinical benefits.
Published on: Sun, 15 Mar 2026 06:00:00 -0400
Authors: Israr Fatima, Abdur Rehman, Hafeez Ur Rehman, Dawood Ahmad Warraich, Mohamed Aldaw, Yuxuan Meng, Mingzhi Liao,
CONCLUSION: JWZQD mitigates PCOS by modulating AGE-RAGE-mediated granulosa-cell senescence through its active compounds quercetin and fisetin. This study supports the clinical potential of JWZQD as an alternative or complementary therapy for PCOS.
Published on: Sun, 15 Mar 2026 06:00:00 -0400
Authors: Hong Tang, Xiaoling Ouyang, Xuet Er Chong, Yuting Yang, Jinrong Fu, Qi Zhou, Linxia Li,
No abstract
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Yuhua Chen, Di Cheng, Zhongcheng Mo, Yuanjie Xie, Siquan Wen, Yi Tan,
No abstract
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Qianqian Li, Yini Wu, Leqin Chen, Ronghui Wang,
CONCLUSION: This study demonstrates that preconception combination therapy with DRSP/EE and orlistat significantly reduces the risk of GDM in overweight or obese women with PCOS. DRSP/EE monotherapy also exhibits a potential protective trend, although the effect is less robust compared to the combination regimen. While differences in HDP and other pregnancy outcomes did not reach statistical significance, the combination therapy group yielded the most favorable clinical profile, achieving the...
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Mingzhen Zhang, Xiangyan Ruan, Lingling Jiang, Yanglu Li, Zecheng Wang, Yanqiu Li, Anming Liu, Alfred O Mueck,
CONCLUSION: Our analysis indicates a general trend of an increase in relevant patent filings with more emphasis on therapeutics. A61K is the largest IPC category under which patents are being filed.
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Maninder Singh, Reema Mediratta, Snehanjali Sahoo, Preeti Khetarpal,
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic disorder associated with insulin resistance (IR), visceral adiposity, and increased cardiometabolic risk. The visceral adiposity index (VAI) is a validated surrogate marker of adipose tissue dysfunction, but its relationship with circulating neurotrophins and adipokine balance in PCOS remains incompletely understood. In this study, 100 women with PCOS were stratified into lower- (n = 50) and higher-risk (n = 50) groups...
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Daniela Koleva-Tyutyundzhieva, Maria Ilieva-Gerova, Elena Becheva, Tanya Deneva, Maria Orbetzova,
While PCOS research has extensively explored genomic, transcriptomic, proteomic, and metabolomic milieus, our study examines the plasma glycome, comparing women with PCOS to age-matched healthy controls. In this observational study, n = 47 women with PCOS were screened and enrolled at the UC Davis Health campus; the comparator group constituted of n = 25 age-matched healthy women. During a study visit, body weight and body composition were measured, and fasted plasma samples were obtained to...
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Madison Holman, Sophie Jie Li, Mary M Ahern, L Renee Ruhaak, Siddika Karakas, Sridevi Krishnan,
Background: Polycystic ovary syndrome (PCOS) is a prevalent endocrine-metabolic disorder with chronic low-grade inflammation and insulin resistance (IR). Elevated C-peptide, a marker of compensatory hyperinsulinemia and reduced adiponectin, an insulin-sensitizing adipokine, contribute to the metabolic dysregulation observed in PCOS. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) and their secretome have immunomodulatory properties via paracrine and epigenetic mechanisms, yet...
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Gunawan Dwi Prayitno, Cynthia Retna Sartika, Tono Djuwantono, Andi Wijaya, Raden Muharam, Yudi Mulyana Hidayat, Rima Haifa, Annisah Zahrah, Keri Lestari,
No abstract
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Piyush Jagdish Balgote, Fathima Nowshad, Avinash Patnaik, Jayanthi Sivaraman,
No abstract
Published on: Sat, 14 Mar 2026 06:00:00 -0400
Authors: Shaoqian Zhao, Yuyao Zou, Zhifeng Wang, Lingxia Ye, Yufei Chen, Zhiwen Cao, Xiaoqiang Xu, Aibo Gao, Xiayang Ying, Mengmin Chen, Kai Qin, Yifei Zhang, Weiqiong Gu, Jiqiu Wang, Guang Ning, Weiqing Wang, Ruixin Liu, Jiabin Jin, Jie Hong,
CONCLUSIONS: Among normoglycaemic women with PCOS, elevated 1hPG was associated with a less favourable cardiometabolic profile and a higher cross-sectional cardiometabolic risk burden. 1hPG may serve as an adjunct marker within routine OGTT interpretation for early cardiometabolic risk enrichment, but prospective validation is needed.
Published on: Fri, 13 Mar 2026 06:00:00 -0400
Authors: Linlin Jiang, Yifan Qian, Ping Pan, Na Di, Jia Huang, Lin Li, Xiaoli Chen, Dongzi Yang,
CONCLUSION: Although the long-term protocol showed higher clinical pregnancy rates in unadjusted analyses, after adjusting for confounders, protocol type was not independently associated with clinical pregnancy. Larger randomized trials are needed to confirm these findings, and adverse outcomes should be assessed in future studies.
Published on: Fri, 13 Mar 2026 06:00:00 -0400
Authors: Shamim Pilevari, Mahnaz Yavangi, Zakieh Yarahmadi, Elahe Talebi Ghane,
Guided by the paradigm of predictive, preventive, and personalized medicine (PPPM/3PM), this study systematically evaluated the epidemiological burden of Polycystic ovarian syndrome (PCOS) and its future trends in countries along the Belt and Road Initiative (BRI). Utilizing data from the Global Burden of Disease Study, we applied Joinpoint regression, Net Drift analysis, age-period-cohort (APC) modeling, and Bayesian APC forecasting. Findings indicated a persistent upward trend in PCOS burden...
Published on: Fri, 13 Mar 2026 06:00:00 -0400
Authors: Xin Xin, Yixuan Wang, Jiaxi Li, Pengpeng Liang,
Female reproductive disorders represent a major global health challenge. Despite their clinical heterogeneity, these conditions share core pathological mechanisms including oxidative stress, chronic inflammation, hormonal imbalance, metabolic dysfunction, extracellular matrix remodeling, and dysregulated cell survival. Current therapies rarely target these interconnected processes, underscoring the need for multi-pathway modulators. Luteolin, a dietary flavone, has emerged as a promising...
Published on: Fri, 13 Mar 2026 06:00:00 -0400
Authors: Lenah S Binmahfouz,